Cresco Labs (CRLBF) Other Non-Current Liabilities (2019 - 2026)
Cresco Labs (CRLBF) posted Other Non-Current Liabilities of $184.9 million for Q1 2026, up 7.83% on a QoQ basis from $171.5 million in Q4 2025, and up 36.15% year-over-year from $135.8 million in Q1 2025.
Cresco Labs (CRLBF) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Cresco Labs' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $184.9 million for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 36.15% year-over-year to $184.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $184.9 million (up 36.15% YoY) and the FY2025 annual result came in at $171.5 million, changed N/A from the prior year.
- Other Non-Current Liabilities was $184.9 million for Q1 2026 at Cresco Labs, up from $171.5 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $184.9 million in Q1 2026 and bottomed at $7.0 million in Q1 2022.
- A 5-year average of $97.2 million and a median of $136.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities slipped 18.14% — and 2025, when it jumped 522.14%.
- Cresco Labs' Other Non-Current Liabilities stood at $12.9 million in 2022, then jumped by 56.67% to $20.2 million in 2023, then jumped by 658.94% to $153.4 million in 2024, then rose by 11.79% to $171.5 million in 2025, then climbed by 7.83% to $184.9 million in 2026.
- Business Quant data shows CRLBF's Other Non-Current Liabilities at $184.9 million in Q1 2026, $171.5 million in Q4 2025, and $165.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Cresco Labs | 254.96 Mn | 99.57 Mn | 75.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 184.91 Mn |
| Dec 31, 2025 | 171.47 Mn |
| Sep 30, 2025 | 165.16 Mn |
| Jun 30, 2025 | 150.54 Mn |
| Mar 31, 2025 | 135.81 Mn |
| Sep 30, 2024 | 153.40 Mn |
| Jun 30, 2024 | 136.64 Mn |
| Mar 31, 2024 | 21.83 Mn |
| Dec 31, 2023 | 20.21 Mn |
| Dec 31, 2022 | 12.90 Mn |
| Jun 30, 2022 | 7.01 Mn |
| Mar 31, 2022 | 7.01 Mn |
| Dec 31, 2021 | 7.00 Mn |
| Sep 30, 2021 | 7.04 Mn |
| Mar 31, 2021 | 8.56 Mn |
| Dec 31, 2020 | 8.56 Mn |
| Dec 31, 2019 | 15.41 Bn |